MAIN BODY
Deregulation momentum and administrative friction in international market expansion
South Korea initially designated botulinum toxin production technology as a National Core Technology in 2010, subsequently expanding the framework in 2016 to include toxin-producing bacterial strains. This statutory mandate requires domestic pharmaceutical manufacturers to obtain inter-agency ministerial approval prior to executing overseas technology transfers or cross-border mergers.
*"Competitiveness in the global botulinum toxin market increasingly depends on manufacturing standards, regulatory expertise and brand recognition rather than access to bacterial strains or basic production technology." — Choi Kyu-jin, Legal Attorney at D&A Law Firm














